ArticleNeuro-ophthalmology (Aeolus Press)2026
Papilledema and Pseudopapilledema in Alagille Syndrome: A Case Report.
Article in Neuro-ophthalmology (Aeolus Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alagille syndrome (ALGS) is a rare, multisystem, autosomal dominant disorder of variable penetrance, typically dominated by the consequences of bile duct paucity and congenital heart disease. Neuro-ophthalmic findings include optic disc swelling and cerebral vascular anomalies. Here, we discuss the care of a lean young man with ALGS and extreme optic disc swelling. He had significant systemic co-morbidities, in the form of renal failure and anticoagulation after cardiac surgery. His disc swelling proved to be due to a combination of pseudopapilledema from ALGS glial proliferation with possible drusen, and true papilledema, with cerebrospinal fluid (CSF) opening pressure of 31 cm H2O at lumbar puncture. Despite renally adjusted acetazolamide and topiramate, field loss beyond blind spot enlargement emerged. CSF shunting was deemed unwise, due to the high revision rate which so often follows. Bilateral optic nerve sheath fenestration was therefore undertaken, and succeeded in reversing the new field loss. Disc swelling did not decline dramatically, due to the ALGS pseudopapilledema as well as the presumed chronicity of the patient's papilledema. Since pseudopapilledema and papilledema can co-exist in ALGS, it is important to adequately distinguish them, ensuring that the emerging visual threat from true papilledema is not overlooked. Systemic comorbidities of the syndrome will need thoughtful care from a co-ordinated multidisciplinary team when treating the papilledema. Screening for cerebral aneurysm is another important principle in the care of patients with ALGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.